Skip to content

Split Face Study of the Duration of Local Anesthetics - Fourth Arm

Characterizing and Comparing the Duration of Local Anesthetic in Dermatologic Surgery - Fourth Arm

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06694714
Enrollment
35
Registered
2024-11-19
Start date
2025-01-21
Completion date
2027-06-01
Last updated
2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Local

Brief summary

This is a research study to compare how long injectable pain medications (anesthetics) commonly used in dermatologic surgery are effective for. The investigators will investigate the role of anesthetic volume on the duration of action at highly vascular sites.

Detailed description

The investigators seek to further investigate how the vascularity of an anatomical region influences the duration of local anesthetics during dermatologic surgery. The investigators hypothesize that regional vascularity, by increasing the rate of uptake and removal of the anesthetic from the infiltrated site, will significantly reduce the duration of action of increased doses of infiltrative anesthesia. Specifically, the investigators will compare the duration of a commonly used local anesthetic (lidocaine ± epinephrine) injected at two different volumes at the nasal ala. The investigators will use a modification of a previously published approach of non-invasive pinprick testing to assess the duration of local anesthesia. The investigators aim to demonstrate that there will be no clinically significant difference in the duration of action of varying volumes of the same local anesthetic injected at bilateral areas of the face. This study record uses the same protocol document of a previous study under Clinical Trials record NCT05767749, but documents a fourth arm for which data will be analyzed separately from data in NCT05767749

Interventions

DRUG0.5 ml lidocaine + epinephrine 1:100,000

0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb

DRUG1.0 ml lidocaine + epinephrine 1:100,000

1.0 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb

Sponsors

Weill Medical College of Cornell University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Two volumes of local anesthetic will be injected into the nasal skin of each participant by a dermatologic surgeon (PI of the study, Dr. Kira Minkis, KM). Dr. Minkis will be unblinded to the laterality of the anesthetic volumes and will not be involved in further assessments.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Male or female ≥ 18 years of age * Normal skin sensation at both nasal ala assessed by pinprick * Ability to provide informed consent

Exclusion criteria

* Previous adverse reaction to local anesthetic or any components of the local anesthetics being evaluated * Pregnant or breastfeeding volunteers (assessed by self-report) * Patients taking monoamineoxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types

Design outcomes

Primary

MeasureTime frameDescription
Time to Return to Baseline Sensation, as Determined by Binary Outcomes (Yes/no) in 15 Minute IncrementsUp to 4 hours.To determine whether the time to return to baseline sensation differs significantly between each pair of anesthetics, the investigators will measure the time to return to baseline sensation at each anesthetized site by asking participants at 15 minute intervals if they can feel a sharp sensation at the site. Sterile needles will be used. The return of the sensitivity will be determined using binary outcomes (yes/no) and recorded on a standardized template. The maximum difference in anesthetic duration that the investigators consider "not different" from a clinical standpoint is 15 minutes.

Countries

United States

Contacts

CONTACTBenedict Ho, BA
beh2024@med.cornell.edu646-962-6647
CONTACTKira Minkis, MD PhD
kim9036@med.cornel.edu646-962-6647
PRINCIPAL_INVESTIGATORKira Minkis, MD, PhD

Weill Medical College of Cornell University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026